Anti-tumor cytostatic mechanism and delayed-type hypersensitivity against a syngeneic murine tumor. Comparison between neonatally thymectomized mice and congenitally athymic nude mice.
We studied the anti-tumor mechanism against a syngeneic tumor using a BALB/c-MA tumor system by cytolysis and cytostasis assays in vitro comparing mice neonatally thymectomized at 1 day or 7 days after birth (NTx-1, NTx-7), sham-operated (sham) mice, and congenitally athymic nude BALB/c mice. NTx-1 mice showed more rapid tumor growth and a slightly lower degree of strong cytostatic activity in peritoneal exudate cells (PEC) than NTx-7 or sham mice. Nude mice showed more rapid MA growth than NTx-1 mice and no cytostatic activity in PEC. After immunization with mitomycin C-treated MA (MMC-MA), NTx-1 mice acquired an immunoprophylactic capacity against MA and showed cytostatic activity and delayed footpad reaction (DFR) to MA, however, nude mice showed no acquisition of such an immunity, or cytostatic activity, or DFR to MA. These differences between NTx-1 and nude mice could be well-explained by less capacity of nude mice to produce a macrophage-activating factor, which activates macrophages to exert cytostasis and DFR. However, NTx-1 mice could not reject MA by immunization with MMC-MA in CFA (MMC-MA/CFA), although such immunized sham mice could eliminate MA completely. Both PEC and spleen cells from Sham mice immunized with MMC-MA/CFA showed cytostatic activity, whereas NTx-1 mice showed cytostatic activity of the same level in PEC and less in spleen cells compared to Sham mice. Cytolytic activity was never detected throughout this study in a BALB/c-MA system. These data suggest that cytostasis plays an important role in antitumor immunity against a syngeneic MA tumor and that two types of cytostasis is included from the standpoint of thymus-dependency of ontogenic development, relatively low and high.
Mitani
M
M
Department of Immunology, Kyushu University, Fukuoka, Japan.
Mori
K
K
Himeno
K
K
Nomoto
K
K
D000818:Animals; D000831:Animals, Newborn / Q000276:immunology*; D002455:Cell Division / Q000187:drug effects; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005354:Fibrosarcoma / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D005620:Freund's Adjuvant / Q000008:administration & dosage; D006968:Hypersensitivity, Delayed / Q000209:etiology / Q000276:immunology*; D008222:Lymphokines / Q000096:biosynthesis; D008262:Macrophage Activation; D016215:Macrophage-Activating Factors; D008748:Methylcholanthrene / Q000008:administration & dosage; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude / Q000276:immunology*; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D013934:Thymectomy
D008222:Lymphokines; D016215:Macrophage-Activating Factors; D008937:Mitomycins; D016685:Mitomycin; D008748:Methylcholanthrene; D005620:Freund's Adjuvant